Survival outcomes in familial and sporadic CEBPA-mutated AML. Kaplan-Meier curves are stratified by CEBPA mutation status: familial (green); sporadic CEBPAsm (black), and sporadic CEBPAdm (red), with P values representing 3-way comparison of curves and direct comparison of familial (Fam) vs sporadic CEBPAsm patients. (A) OS in all sporadic and familial patients. (B) OS in sporadic and familial patients ≤45 years. (C) Survival after relapse for all patients with relapse. Familial patients demonstrated a median survival of 8 years, whereas sporadic AML patients, in particular CEBPAsm, displayed a rapid decline in survival within 2 years of relapse.